Table 4.
ICERs of scenario analyses from the Chinese healthcare perspective (CNY per QALY gained)
| PEACE | BERSON | SuValue® LDL-C ≥ 100 mg/dl |
SuValue® LDL-C ≥ 70 mg/dl |
|||||
|---|---|---|---|---|---|---|---|---|
| Evo 140mgQ2W | Evo 420mgQM | Evo 140mgQ2W | Evo 420mgQM | Evo 140mgQ2W | Evo 420mgQM | Evo 140mgQ2W | Evo 420mgQM | |
| Time horizon | ||||||||
| 5 years | 560431.63 | 862489.78 | 501332.97 | 893539.69 | 195951.91 | 242966.70 | 322809.94 | 557316.71 |
| 10 years | 284569.36 | 440560.92 | 242330.14 | 439597.72 | 94332.72 | 194182.08 | 160883.45 | 285355.56 |
| 15 years | 191287.82 | 296835.37 | 154973.97 | 284122.89 | 62166.54 | 131380.50 | 107590.05 | 193482.78 |
| 20 years | 152155.45 | 236588.60 | 114428.44 | 211855.12 | 47781.40 | 103208.66 | 83668.90 | 152268.70 |
| 30 years | 134240.70 | 209956.59 | 86535.32 | 163514.29 | 37302.63 | 84166.61 | 67030.66 | 124934.42 |
| 35 years | 133083.42 | 208719.66 | 83376.17 | 158919.09 | NA | NA | NA | NA |
| Starting age | ||||||||
| 65-year | 121365.52 | 172717.45 | 73383.57 | 138037.76 | NA | NA | NA | NA |
| 70-year | 103267.71 | 150351.27 | 56517.58 | 108060.03 | 39605.72 | 87392.58 | 70034.35 | 129059.14 |
| 75-year | 84946.74 | 126891.51 | 42483.76 | 83985.21 | 30553.67 | 68195.31 | 53678.13 | 99970.03 |
| Discount rate | ||||||||
| 3% | 123519.88 | 192790.91 | 83849.77 | 157503.59 | 36035.97 | 80462.88 | 64207.24 | 119040.93 |
| 6% | 145241.79 | 226352.26 | 100806.54 | 188192.28 | 43473.21 | 95365.52 | 76801.17 | 140974.87 |
| Annual Cost of Stains (CNY) a | ||||||||
| 118.86 | 131102.46 | 212813.67 | 93705.52 | 176282.05 | 38710.07 | 88018.74 | 70251.67 | 131192.08 |
| 5470.28 | 134976.64 | 216654.87 | 95526.50 | 178110.59 | 43004.30 | 92312.97 | 74550.88 | 135491.29 |
| Costs of CV-related death b | ||||||||
| Death due to stroke 1 | 116570.06 | 193592.63 | 73068.07 | 155525.57 | 16745.35 | 66054.01 | 48025.65 | 108966.06 |
| Death due to stroke 2 | 130382.94 | 207405.52 | 87351.56 | 169888.68 | 32541.32 | 81849.98 | 63999.21 | 124939.62 |
| Death due to MI 1 | 118319.42 | 195341.99 | 68158.82 | 150384.52 | 6528.07 | 55836.73 | 39090.98 | 100031.39 |
| Death due to MI 2 | 92301.26 | 169323.84 | 35964.22 | 117891.62 | Dominance | 17416.88 | 1113.88 | 62054.29 |
| Utility c | ||||||||
| Higher utility | 156999.82 | 244782.59 | 103011.41 | 193226.79 | 45005.11 | 99255.17 | 80019.62 | 147327.16 |
| Lower utility | 126564.51 | 197330.08 | 89484.04 | 166987.79 | 38284.51 | 84433.42 | 67616.20 | 124490.76 |
| UK- utility | 146062.51 | 227729.93 | 100800.52 | 187476.68 | 42461.83 | 93646.16 | 74998.51 | 138082.62 |
| Hospital classification | ||||||||
| County hospitals | 154811.12 | 231833.69 | 113682.98 | 196641.29 | 67932.09 | 117240.76 | 98423.88 | 159364.30 |
| County-level municipal hospitals | 150510.37 | 227532.95 | 108608.40 | 191463.97 | 60612.92 | 109921.59 | 91418.36 | 152358.77 |
| Prefecture-level municipal hospitals | 136460.69 | 213483.27 | 93365.00 | 175916.39 | 38748.53 | 88057.20 | 70387.91 | 131328.32 |
| Provincial hospitals | 134431.86 | 211454.44 | 90173.78 | 172658.18 | 34080.28 | 83388.94 | 65984.28 | 126924.69 |
| Hospitals directly under the Health Commission | 129164.77 | 206187.35 | 84385.48 | 166754.78 | 25788.08 | 75096.74 | 58021.98 | 118962.39 |
CNY, Chinese Yuan; Dominance, ICERs, incremental cost-effectiveness ratio; Lower cost, higher utility; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not applicable
italic text: ICERs below CNY 85698 (US$12741); bold text: ICERs above CNY 257094 (US$38224).
a: the maximum and minimum annual cost of statins, more detailed parameters are shown in Supplementary Tables S4
b: CV-related mortality costs used in other CEA studies and beyond the scope of sensitivity analysis, more detailed parameters are shown in Supplementary Tables S5
c: Utility used in other CEA studies and beyond the scope of sensitivity analysis, more detailed parameters are shown in Supplementary Tables S6